CAPRIE

Clopidogrel vs. Aspirin in Patients at Risk of Ischemic Events. A trial comparing an antiplatelet agent, clopidogrel, to aspirin in decreasing the risk of stroke, infarction, or vascular death in patients with evidence of vascular disease
Conclusion Long-term clopidogrel is more effective than aspirin in decreasing composite end-points for patients with symptomatic ASHD; clopidogrel’s safety is comparable to medium dose aspirin

CAPRIE

Cardiology A clinical trial–Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events which compared the efficacy of the antiplatelet agent, clopidogrel, with aspirin therapy as a stroke prophylaxis. See Clopidogrel.

Acronym

Definition

CAPRIE➣Clopidogrel vs Aspirin in Patients at Risk of Ischemic Events